GLP-1 medicines and diabetic retinopathy: the honest eye story
A large semaglutide trial called SUSTAIN-6 found a small increase in diabetic retinopathy complications, with a hazard ratio of about 1.76. This is thought to be partly linked to a fast drop in blood sugar, because rapid improvement in glucose control can cause a temporary worsening of retinopathy, a known effect of intensive diabetes treatment and not unique to GLP-1 medicines. The honest picture is that people with existing diabetic retinopathy should be monitored with eye checks when starting a GLP-1 and tightening sugar control, while the long-term effect of good sugar control is to reduce retinopathy. Talk to your diabetologist and your eye doctor.
Unlock the complete article
Register with just your mobile number and OTP. No password and no payment.